These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 22283238)

  • 21. The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost.
    Li Yim JF; Montgomery DM
    Curr Med Res Opin; 2011 Aug; 27(8):1499-502. PubMed ID: 21651425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: latanoprost in monotherapy vs timolol and dorzolamide in association.
    Italian Multicentric Open Randomized Study under the aegis of A.I.S.G.: Final Results and Official Report
    Acta Ophthalmol Scand Suppl; 2000; (232):49-50. PubMed ID: 11235535
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
    Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
    Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy.
    Shin D
    Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S163-8. PubMed ID: 10665519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma.
    Konstas AG; Kozobolis VP; Tersis I; Leech J; Stewart WC
    Eye (Lond); 2003 Jan; 17(1):41-6. PubMed ID: 12579169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension.
    Miglior S; Grunden JW; Kwok K;
    Eye (Lond); 2010 Jul; 24(7):1234-42. PubMed ID: 20019759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.
    Pfeiffer N;
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):1065-71. PubMed ID: 21499770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.
    Petounis A; Mylopoulos N; Kandarakis A; Andreanos D; Dimitrakoulias N
    J Glaucoma; 2001 Aug; 10(4):316-24. PubMed ID: 11558817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latanoprost versus combined timolol and dorzolamide.
    Bron AM; Emmerich KH
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S148-54. PubMed ID: 12204712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination.
    Sellem E; Rouland JF; Baudouin C; Bron A; Denis P; Nordmann JP; Renard JP
    BMC Ophthalmol; 2010 Mar; 10():10. PubMed ID: 20346127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.